AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms

Leading cannabinoid biotechnology company files U.S. provisional patent application on a chewing gum composition comprising cannabinoids and feverfew extract for the treatment of symptoms that accompany migraines

Leading cannabinoid biotechnology company files U.S. provisional patent application on a chewing gum composition comprising cannabinoids and feverfew extract for the treatment of symptoms that accompany migraines

READ MORE: http://www.globenewswire.com/news-release/2019/05/09/1820824/0/en/AXIM-Biotechnologies-Files-New-U-S-Provisional-Patent-for-Cannabis-Gum-as-a-Treatment-for-Migraine-Symptoms.html